RFP
AVBP icon

Root Financial Partners’s ArriVent BioPharma AVBP Stock Holding History

Root Financial Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18
Closed -$415 – 3266
2026
Q1 		$415 Buy
+18
New +$407 ﹤0.01% 2925

Other funds holding AVBP

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Root Financial Partners's AVBP Position: Q2 2026 in Review

Root Financial Partners sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 18 shares — an estimated $415 sold.

Root Financial Partners first reported a position in AVBP in Q1 2026 and held it in 1 quarter. The position peaked at $415 in Q1 2026. 18 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Root Financial Partners reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 18 ArriVent BioPharma shares in Q2 2026, an estimated $415.
  • Root Financial Partners first reported a position in ArriVent BioPharma in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's ArriVent BioPharma position peaked at $415 in Q1 2026.
  • 18 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.